Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersKey papersJournalsOpen accessInstitutions
ScholarIQanswers from OpenAlex

Bone health and treatments

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the use of bisphosphonates in the treatment of bone metastases and associated complications, particularly osteonecrosis of the jaw. It explores the mechanisms of action, clinical features, and therapeutic opportunities for bisphosphonates in cancer treatment, with a specific emphasis on prostate and breast cancer. The papers also discuss the role of bisphosphonates in maintaining bone health and preventing skeletal complications in cancer patients.

297
Works

How has Bone health and treatments's publication output changed over time?

ScholarIQpublication output · 1997–2016

Output grew0% over the shown period — from 1 works in 1997 to 1 in 2016.

1
3
2
2
1
1
1
1
1
1
1997200220032006200720092011201220142016

What are the most-cited papers on Bone health and treatments?

ScholarIQmost cited works
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi, Michael A. Carducci, Matthew R. Smith, Ronaldo Damião, Janet E. Brown, Lawrence I. Karsh, Piotr Milecki, Neal D. Shore, Michael Rader, Huei Wang, Qi Jiang, Sylvia Tadros, Roger Dansey, Carsten Goessl
The Lancet. 20111,972 CitationsOPEN ACCESS
Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research
Sundeep Khosla, David B. Burr, Jane A. Cauley, David W. Dempster, Peter R. Ebeling, Dieter Felsenberg, Robert F. Gagel, Vincente Gilsanz, Theresa A. Guise, Sreenivas Koka, Laurie K. McCauley, Joan McGowan, Marc D. McKee, Suresh Mohla, David G. Pendrys, Lawrence G. Raisz, Salvatore L. Ruggiero, David Shafer, Lillian Shum, Stuart L. Silverman, Catherine Van Poznak, Nelson B. Watts, Sook-Bin Woo, Elizabeth Shane
Journal of Bone and Mineral Research. 20071,650 CitationsOPEN ACCESS
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Paul L. Nguyen, Shabbir M.H. Alibhai, Shehzad Basaria, Anthony V. D’Amico, Philip W. Kantoff, Nancy L. Keating, David F. Penson, Derek J. Rosario, Bertrand Tombal, Matthew Smith
European Urology. 2014824 Citations
Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer
Matthew R. Smith, James A. Eastham, Donald M. Gleason, Daniel Shasha, Simon Tchekmedyian, Norman R. Zinner
The Journal of Urology. 2003649 Citations
Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure
Joan C. Lo, Felice O’Ryan, Nancy P. Gordon, Jingrong Yang, Rita L. Hui, Dan C. Martin, Mathew D. Hutchinson, Phenius V. Lathon, Gabriela Sánchez, Paula Silver, Malini Chandra, Carolyn McCloskey, Judy A. Staffa, Mary E. Willy, Joe V. Selby, Alan S. Go
S2672396. 2009492 CitationsOPEN ACCESS

Where is Bone health and treatments research published, and who funds it?

ScholarIQvenues & funding sources

TOP FUNDERS

National Science Foundation
NIH
Wellcome Trust
European Research Council
Funder breakdown is a member featureSign up free to unlock

How much of the research on Bone health and treatments is open access?

ScholarIQopen access share
47%OPEN ACCESS
Gold
0%
Green
20%
Hybrid
0%
Bronze
27%
Closed
53%

Related on ScholarIQ

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Paper
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Paper
Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development
Paper
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Paper
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Paper
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Paper
470M+ articles · free account